A phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer

International Journal of Radiation Oncology Biology Physics

Volumn 87, Issue 3, 2013, Pages 479-486

  Fury, Matthew G ^a,b   Lee, Nancy Y ^a   Sherman, Eric ^a,b   Ho, Alan L ^a,b   Rao, Shyam ^a   Heguy, Adriana ^a   Shen, Ronglai ^a   Korte, Susan ^a   Lisa, Donna ^a   Ganly, Ian ^a   Patel, Snehal ^a   Wong, Richard J ^a   Shaha, Ashok ^a   Shah, Jatin ^a   Haque, Sofia ^a   Katabi, Nora ^a   Pfister, David G ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOSE LIMITING TOXICITY; EUKARYOTIC PROTEIN SYNTHESIS; HEAD-AND-NECK CANCER; IMMUNOHISTOCHEMISTRY; INTENSITY MODULATED RADIATION THERAPY; MAXIMUM TOLERATED DOSE; METHODS AND MATERIALS; SQUAMOUS CELL CARCINOMA;

DISEASES; PLATINUM COMPOUNDS; SURGERY;

RADIOTHERAPY;

CISPLATIN; EVEROLIMUS; INITIATION FACTOR 4E;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; DRUG DOSE ESCALATION; DYSPHAGIA; FAILURE TO THRIVE; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; INTENSITY MODULATED RADIATION THERAPY; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MOUTH CANCER; MOUTH PAIN; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CANCER; NECK CANCER; OPEN STUDY; OROPHARYNX CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECOMMENDED DRUG DOSE; RECURRENT CANCER; SALIVARY GLAND CANCER; SCALP TUMOR; SORE THROAT;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; EUKARYOTIC INITIATION FACTOR-4E; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM PROTEINS; PROSPECTIVE STUDIES; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84884885139     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.06.2043     Document Type: Article

References (45)

1. D.G. Pfister, KK Ang, and DM Brizel National comprehensive cancer network clinical practice guidelines in oncology. Head and neck cancers J Natl Compr Canc Netw 2011 596 650
2. A.A. Molinolo, SM. Hewitt, and P Amornphimoltham Dissecting the Akt/mammalian target of rapamycin signaling network: Emerging results from the head and neck cancer tissue array initiative Clin Cancer Res 13 2007 4964 4973
3. L.G. Morris, BS. Taylor, and TG Bivona Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers Proc Natl Acad Sci U S A 108 2011 19024 19029
4. C.O. Nathan, N. Amirghahari, and F Abreo Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway Clin Cancer Res 10 2004 5820 5827
5. M.G. Fury, M. Drobnjak, and C Sima Tissue microarray analysis demonstrates association between p16 and phosphorylated eIF4E in tonsillar squamous cell carcinoma Head Neck 22 2011 1340 1345
6. A.A. Molinolo, C. Marsh, and M El Dinali mTOR as a molecular target of HPV-associated oral and cervical squamous carcinomas Clin Cancer Res 18 2012 2558 2568
7. C.-A.O. Nathan, S. Franklin, and FW Abreo Analysis of surgical margins with the molecular marker eIF4E: A prognostic factor in patients with head and neck cancer J Clin Oncol 17 1999 2909 2914
8. C.-A.O. Nathan, N. Amirghahari, and X Rong Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer Cancer Res 67 2007 2160 2168
9. R.A. Figlin, E. Brown, and AJ Armstrong NCCN task force report: mTOR inhibition in solid tumors J Natl Compr Canc Netw 6 Suppl. 5 2008 S1 S22
10. D.D. Sarbassov, SM. Ali, and S Sengupta Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB Mol Cell 22 2006 159 168
11. Z. Zeng, DD. Sarbassov, and IJ Samudio Rapamycin derivatives reduce mTORC2 signaling and inhibit Akt activation in AML Blood 109 2007 3509 3512
12. O. Ekshyyan, Y. Rong, and X. Rong Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma Mol Cancer Ther 8 2009 2255 2265
13. J.M. Albert, KW. Kim, and C. Cao Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization in breast cancer Mol Cancer Ther 5 2006 1183 1189
14. C. Cao, T. Subhawong, and JM Albert Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells Cancer Res 66 2006 10040 10047
15. P.C. Manegold, C. Paringer, and U. Kulka Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (everolimus) increases radiosensitivity in solid cancer Clin Cancer Res 14 2008 892 900
16. N. Aissat, C. Le Tourneau, and A. Ghoul Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines Cancer Chemother Pharmacol 62 2008 305 313
17. I. Beuvink, A. Boulay, and S. Fumagalli The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damage induced apoptosis though inhibition of p21 translation Cell 120 2005 747 759
18. W.H. Mondesire, W. Jian, and H Zhang Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells Clin Cancer Res 10 2004 7031 7042
19. Y. Shi, A. Frankel, and LG Radvanyi Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro Cancer Res 55 1995 1982 1988
20. J. Baselga, M. Campone, and M. Piccart Everolimus in post-menopausal hormone-receptor-positive advanced breast cancer N Engl J Med 366 2012 520 529
21. R.J. Motzer, B. Escudier, and S Oudard Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III study Lancet 372 2008 449 456
22. J.C. Yao, MH. Shah, and T Ito Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 2011 514 523
23. M.G. Fury, E. Sherman, and S Haque A phase I study of everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors Cancer Chemother Pharmacol 69 2012 591 598
24. S. Franklin, T. Pho, and FW Avbreo Detection of the proto-oncogene eIF4E in larynx and hypopharynx cancers Arch Otolaryngol Head Neck Surg 125 1999 177 182
25. S. Wang, RV. Lloyd, and MJ Hutzler Expression of eukaryotic translation initiation factors 4E and 2alpha correlates with progression of thyroid carcinoma Thyroid 11 2001 1101 1107
26. M. Janakiraman, E. Vakiani, and Z. Zeng Genomic and biologic characterization of exon 4 KRAS mutations in human cancer Cancer Res 70 2010 5901 5911
27. E. Vakiani, M. Janakiraman, and R Shen Comparative genomic analysis of primary versus metastatic colorectal carcinomas J Clin Oncol 30 2012 2956 2962
28. D.L. Reidy, E. Vakiani, and MG Fakih Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer J Clin Oncol 28 2010 4240 4246
29. A. O'Donnell, S. Faivre, and HA Burris Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors J Clin Oncol 26 2008 1588 1595
30. J. Bernier, C. Domenge, and M Ozsahin Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer New Engl J Med 350 2004 1945 1952
31. J.S. Cooper, TF. Pajak, and AA Forastiere Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck New Engl J Med 350 2004 1937 1944
32. J.-M. Bachaud, E. Cohen-Jonathan, and C Alzieu Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck cancer: Final report of a randomized trial Int J Radiat Oncol Biol Phys 36 1996 999 1004
33. M.G. Fury, and J.P. Shah Induction chemotherapy in the management of head and neck cancer J Surg Oncol 101 2010 292 298
34. D.J. Adelstein, J. Moon, and E Hanna Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/ concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (s0216) Head Neck 32 2010 221 228
35. T. Ettl, S. Schwarz-Furlan, and F Haubner The PI3K/Akt/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation Oral Oncol 48 2012 822 830
36. B.B. Ma, VW Lui, and EP Hui The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines Invest New Drugs 28 2009 413 420
37. S.A. Piha-Paul, P.R. Cohen, and R. Kurzrock Salivary duct carcinoma: Targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus J Clin Oncol 29 2011 e727 e730
38. A. Agrawal, MJ. Frederick, and CR Pickering Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1 Science 333 2011 1154 1156
39. M.G. Fury, E. Sherman, and A.L. Ho A phase I study of everolimus plus docetaxel + cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer Cancer 119 2013 1823 1831
40. W. Qiu, F Schonleben, and X Li PIK3CA mutations in head and neck squamous cell carcinoma Clin Cancer Res 12 2006 1441 1446
41. W. Qiu, G-X Tong, and S Manolidis Novel mutant enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer Int J Cancer 122 2008 1189 1194
42. N. Stransky, A.M. Egloff, and A.D. Tward The mutational landscape of head and neck squamous cell carcinoma Science 333 2011 1157 1160
43. F.C. Holsinger, SA. Piha-Paul, and F Janku Biomarker-directed therapy of squamous carcinomas of the head and neck: Targeting PI3K/PTEN/mTOR pathway J Clin Oncol 31 2013 e137 e140
44. J.M. Spangle, and K. Munger The human papillomavirus type 16 E6 oncoprotein activates mTORC1 signaling and increases protein synthesis J Virol 84 2010 9398 9407
45. CR Pickering, J Zhang, and SY Yoo Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers Cancer Discov 3 2013 770 781